VivoSeq
Other

Prolonged

0

Pipeline Programs↗

10

Active Trials↗

6

Companies Involved↗

Prolonged is an early-stage landscape with 0 programs across 6 companies. The most active players are Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Berlin-Chemie AG Menarini Group, CSL Behring.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

0 programs

PreclinicalB

Berlin-Chemie AG Menarini Group

0 programs

PreclinicalCSL Behring logo

CSL Behring

0 programs

PreclinicalL

Lee's Pharmaceutical Limited

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalRoche logo

Roche

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

42

clinical trials

Completed28 · 67%
Not yet recruiting4 · 10%
Active, not recruiting4 · 10%
Withdrawn2 · 5%
Recruiting2 · 5%
Unknown status1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

42 trials

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06046313·120 enrolled
MDMA-assisted Massed Prolonged Exposure for PTSD
Recruiting·—·Phase 3·NCT06117306·20 enrolled
Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects
Active, not recruiting·—·Phase 1·NCT03139305·30 enrolled
A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions
Active, not recruiting·BBerlin-Chemie AG Menarini Group·Phase 1·NCT07091669·46 enrolled
A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD
Active, not recruiting·UUniversity of Pennsylvania·Phase 4·NCT04961190·302 enrolled
A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State
Active, not recruiting·BBerlin-Chemie AG Menarini Group·Phase 1·NCT07146711·33 enrolled
Ketamine HCl Prolonged Release Oral Tablets for CRPS
Not yet recruiting·UUniversity of Southern California·Phase 2·NCT06419985·65 enrolled
Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy
Not yet recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT06861374·2,400 enrolled
Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions
Not yet recruiting·PPharma Nueva·Phase 1·NCT06316336·44 enrolled
Efficacy of Bicarbonate on the Risk of Assisted Delivery in Nulliparous Women With Prolonged Labour
Not yet recruiting·—·N/A·NCT07321379·1,520 enrolled
Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)
Completed·GGenuine Research Center, Egypt·Phase 1·NCT05767632·30 enrolled
To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects
Completed·NNanexa AB·Phase 1·NCT05643248·9 enrolled
Effects of Oxytocin on the Functional Architecture of the Brain Before and After Prolonged Naturalistic Fear Induction
Completed·UUniversity of Electronic Science and Technology of China·N/A·NCT05896553·69 enrolled
A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01900587·64 enrolled
Pilot Pharmacokinetic Study of a Prolonged-release Formulation of St. John's Wort Extract Ze 117
Completed·MMax Zeller Soehne AG·Phase 1·NCT02505191·10 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)